(1 - 7 from 9
)
WellPoint's CEO Braly Resigns Amid Shareholder Criticism
www.bloomberg.com
[Bloomberg] - “They need a CEO who has demonstrated by his or her experience that they have the expertise to run a company the size that WellPoint will be, and they need them sooner rather than later,” said Erik Gordon, a professor at the University of Michigan's
Coupons an incentive to stick with brand-name drugs
seattletimes.com
[The Seattle Times] - "On a big drug, every day that you can delay the sales drop is a happy day at the drug company," says Erik Gordon, a professor at the University of Michigan's Ross School of Business who follows the drug industry. Developing drugs requires up to a
Bristol-Myers suspends hepatitis C treatment study
www.huffingtonpost.com
[Huffington Post] - Analyst Erik Gordon, a professor at the University of Michigan's Ross School of Business, said the study suspension makes the Inhibitex acquisition look like a mistake for Bristol-Myers. Hepatitis C is a virus that can lead to life-threatening liver
Erik Gordon: The Path Less Traveled…to Success ...
news.umich.edu
Erik Gordon is one of the University of Michigan's most quoted professors in mainstream media, but his path to this status was not a traditional one. Hear how Erik's meandering career path has led him to a faculty position at one of the most prestigious business schools in the country.
sorted by relevance / date